Orexigen Therapeutics, Inc. news

   Watch this stock
Showing stories 1 - 10 of about 69   

Articles published

OREX 5.89 +0.23 (4.06%)
price chart
Orexigen Therapeutics Reports Corporate and Financial Results for the Second ...
SAN DIEGO, Aug. 7, 2014 /PRNewswire/ -- Orexigen(R) Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity, today announced corporate and financial results for the second quarter ended June 30, 2014.
Orexigen Therapeutics, Inc. (OREX) Reports In-Line Q2 Loss of 21c/Share  StreetInsider.com (subscription)
Orexigen Therapeutics (OREX) Releases Quarterly Earnings Results, Meets ...  Ticker Report
Related articles »  
Orexigen Therapeutics Misses Second-Quarter Estimates
The substantial increase in revenues is based on the expected payment of $100 million from Takeda Pharmaceutical Company Limited, contingent to the approval of Orexigen's obesity drug NB32. The Food and Drug Administration (FDA) will reveal its ...
Orexigen Therapeutics Reports Wider Q2 Loss as Costs Mount - Analyst Blog  NASDAQ
Related articles »  
Small Cap Obesity Stock Orexigen Therapeutics (OREX) Awaits Its Fate (ARNA ...
Small cap biotech Orexigen Therapeutics, Inc (OREX) is developing an obesity drug with a FDA Prescription Drug User Fee Act (PDUFA) action date set for September 11 plus a look at the so-so performance of obesity stocks Arena Pharmaceuticals, Inc ...
Eye-Catching Stocks - Tuesday Morning Corporation (NASDAQ:TUES ...
Orexigen Therapeutics, Inc. (NASDAQ:OREX) declared corporate and financial results for the second quarter ended June 30, 2014.
Orexigen Therapeutics to Host Second Quarter 2014 Financial Results ...
SAN DIEGO, July 31, 2014 /PRNewswire/ -- Orexigen(R) Therapeutics, Inc. (Nasdaq: OREX) will announce financial results for the second quarter 2014, on Thursday, August 7, 2014 before markets open.
Stocks to Watch: Lockheed Martin (NYSE:LMT), Orexigen Therapeutics ...  eMarketsDaily
News Recap- Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR), Penn Virginia ...  Techsonian (press release)
Related articles »  
Market Momentum on Biotech Stocks -- IsoRay, Neurocrine Biosciences, OPKO ...
Investor-Edge has initiated coverage on the following equities: IsoRay Inc. (NYSE MKT: ISR), Neurocrine Biosciences Inc. (NASDAQ: NBIX), OPKO Health Inc. (NYSE: OPK), Orexigen Therapeutics Inc. (NASDAQ: OREX), and Gilead Sciences Inc. (NASDAQ: ...
Related articles »  
Possible Delay In Orexigen Approval Process In Europe
Orexigen (NASDAQ:OREX) announced on July 30 that the company has received a List of Outstanding Issues (LOI) in the form of a 180 day Letter from the Committee for Medical Products For Human Use (OTCQB:CHMP) regarding the anti-obesity drug ...
Outstanding issues delay Orexigen's naltrexone/bupropion drug approval ...  Healio
CHMP Has More Issues with Weight Loss Drug  Drug Discovery & Development
Related articles »  
Stocks Alert- Orexigen Therapeutics, Inc. (OREX), Q Arena Pharmaceuticals, Inc ...
Stamford, Connecticut - 18th Aug 2014- (Techsonian) - Orexigen Therapeutics, Inc. (NASDAQ:OREX), a biopharmaceutical company, focuses on the development of pharmaceutical product candidates for the treatment of obesity.
News Recap - Walter Energy, Inc. (WLT), Orexigen Therapeutics, Inc. (NASDAQ ...
Stamford, Connecticut - 19th Aug 2014- (Techsonian) - Walter Energy, Inc. (NYSE:WLT) disclosed results for the quarter ended June 30, 2014.
Related articles »  
Stocks to Track:Orexigen Therapeutics, Inc. (OREX), Allied Nevada Gold Corp ...
Las Vegas, NV - July 28, 2014 - (Tech Sonian) �Orexigen Therapeutics, Inc. (OREX)a biopharmaceutical company, focuses on the development of pharmaceutical product candidates for the treatment of obesity.
Related articles »